After phase 2 flop, Novo Nordisk says its NASH work is 'still very much on track'

Non-alcoholic steatohepatitis (NASH) has been among the most elusive targets in the biopharma industry in recent years. And just as the condition is growing in an increasingly obese world, so too is the roster of companies trying and failing to develop a remedy.